Cell Therapeutics (CTIC +2.2%) announces data from a Phase 2 study of a tosedostat/ cytarabine or decitabine combo in newly diagnosed AML or MDS.
First dose cohort results: 54% had either CR or CRi.
Primary objective achieved: 82% of patients alive after four months.
Median OS for both study arms: ~12 months.
Side effects (associated mostly with the cytarabine arm): Febrile neutropenia, pulmonary infections, sepsis in 50%, 31%, and 19% of patients, respectively. (PR)